Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Intensity Therapeutics, Inc. Common stock (INTS) Competitors

Intensity Therapeutics, Inc. Common stock logo

INTS vs. PLX, CGEN, EXOZ, EDIT, TARA, VIGL, FATE, ACOG, ALEC, and IVVD

Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Protalix BioTherapeutics (PLX), Compugen (CGEN), Exozymes (EXOZ), Editas Medicine (EDIT), Protara Therapeutics (TARA), Vigil Neuroscience (VIGL), Fate Therapeutics (FATE), Alpha Cognition (ACOG), Alector (ALEC), and Invivyd (IVVD). These companies are all part of the "biological products, except diagnostic" industry.

Intensity Therapeutics, Inc. Common stock vs.

Protalix BioTherapeutics (NYSE:PLX) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Protalix BioTherapeutics has higher revenue and earnings than Intensity Therapeutics, Inc. Common stock. Intensity Therapeutics, Inc. Common stock is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protalix BioTherapeutics$59.76M2.23$8.31M$0.0441.88
Intensity Therapeutics, Inc. Common stockN/AN/A-$10.54M-$1.07-0.34

Protalix BioTherapeutics received 3 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 90.91% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 81.25% of users gave Protalix BioTherapeutics an outperform vote.

CompanyUnderperformOutperform
Protalix BioTherapeuticsOutperform Votes
13
81.25%
Underperform Votes
3
18.75%
Intensity Therapeutics, Inc. Common stockOutperform Votes
10
90.91%
Underperform Votes
1
9.09%

In the previous week, Protalix BioTherapeutics had 6 more articles in the media than Intensity Therapeutics, Inc. Common stock. MarketBeat recorded 6 mentions for Protalix BioTherapeutics and 0 mentions for Intensity Therapeutics, Inc. Common stock. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Protalix BioTherapeutics' score of 0.16 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.

Company Overall Sentiment
Protalix BioTherapeutics Neutral
Intensity Therapeutics, Inc. Common stock Very Positive

Intensity Therapeutics, Inc. Common stock has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Intensity Therapeutics, Inc. Common stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics-21.03% -30.89% -11.74%
Intensity Therapeutics, Inc. Common stock N/A -209.73%-149.19%

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 18.6% of Intensity Therapeutics, Inc. Common stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Protalix BioTherapeutics has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, indicating that its share price is 303% more volatile than the S&P 500.

Protalix BioTherapeutics presently has a consensus price target of $15.00, indicating a potential upside of 795.52%. Intensity Therapeutics, Inc. Common stock has a consensus price target of $8.50, indicating a potential upside of 2,261.11%. Given Intensity Therapeutics, Inc. Common stock's higher probable upside, analysts plainly believe Intensity Therapeutics, Inc. Common stock is more favorable than Protalix BioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Intensity Therapeutics, Inc. Common stock
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Protalix BioTherapeutics beats Intensity Therapeutics, Inc. Common stock on 9 of the 17 factors compared between the two stocks.

Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically

Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INTS vs. The Competition

MetricIntensity Therapeutics, Inc. Common stockBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$33.23M$2.92B$5.34B$8.44B
Dividend YieldN/A1.68%5.21%4.11%
P/E Ratio-0.3631.1726.9019.78
Price / SalesN/A402.06389.48118.91
Price / CashN/A168.6838.2534.62
Price / Book0.383.246.784.52
Net Income-$10.54M-$72.35M$3.23B$248.23M

Intensity Therapeutics, Inc. Common stock Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INTS
Intensity Therapeutics, Inc. Common stock
1.9788 of 5 stars
$0.36
-86.2%
$8.50
+2,261.1%
-92.1%$33.23MN/A-0.362,021Positive News
Analyst Downgrade
Gap Up
PLX
Protalix BioTherapeutics
2.1904 of 5 stars
$1.60
+9.2%
$15.00
+840.4%
+40.2%$126.83M$53.40M-12.27200High Trading Volume
CGEN
Compugen
1.743 of 5 stars
$1.40
+6.1%
$4.00
+185.7%
-25.3%$124.93M$27.86M70.0070News Coverage
Earnings Report
Analyst Revision
EXOZ
Exozymes
N/A$14.81
+18.1%
N/AN/A$123.93MN/A0.0029Gap Up
EDIT
Editas Medicine
4.2628 of 5 stars
$1.48
-4.1%
$5.36
+263.0%
-72.8%$123.68M$32.31M-0.58230
TARA
Protara Therapeutics
2.9944 of 5 stars
$3.19
-2.4%
$20.40
+539.5%
+10.9%$123.07MN/A-1.1330News Coverage
Positive News
Analyst Forecast
Gap Up
VIGL
Vigil Neuroscience
3.1391 of 5 stars
$2.52
-0.4%
$16.25
+544.8%
-34.0%$117.61MN/A-1.2240Trending News
Analyst Forecast
Gap Up
FATE
Fate Therapeutics
4.3437 of 5 stars
$1.02
-4.6%
$4.60
+350.8%
-68.4%$116.94M$13.63M-0.62550
ACOG
Alpha Cognition
1.6715 of 5 stars
$7.03
-5.6%
$20.00
+184.5%
N/A$112.62MN/A-2.75N/AEarnings Report
ALEC
Alector
3.7761 of 5 stars
$1.12
-6.7%
$4.00
+257.1%
-76.8%$111.99M$88.34M-0.66270News Coverage
Positive News
Gap Up
IVVD
Invivyd
2.9203 of 5 stars
$0.92
+9.7%
$7.52
+718.0%
-65.4%$110.23M$25.38M-0.47100Earnings Report

Related Companies and Tools


This page (NASDAQ:INTS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners